Baidu
map

内分泌科

订阅

MedSci主页 / 所有栏目 / 内分泌科

Diabetes Obes Metab：依帕列净多重功效获新证据

2014-05-06 伊文 中华医学会糖尿病学分会

依帕列净糖尿病
关注

近期发表的一项囊括10项随机对照研究的Meta分析表明，对于2型糖尿病患者，与安慰剂相比，钠葡萄糖共同转运蛋白2(SGLT-2)抑制剂依帕列净(empagliflozin)除了能有效降低血糖外，还有助于减轻体重和降低血压。(Diabetes Obes Metab. 2014年4月26日在线版)在该分析中，依帕列净以10 mg或25 mg应用对HbA1c水平的降低效果均显著优于安慰剂，其中25 mg

近期发表的一项囊括10项随机对照研究的Meta分析表明，对于2型糖尿病患者，与安慰剂相比，钠葡萄糖共同转运蛋白2(SGLT-2)抑制剂依帕列净(empagliflozin)除了能有效降低血糖外，还有助于减轻体重和降低血压。(Diabetes Obes Metab. 2014年4月26日在线版)

在该分析中，依帕列净以10 mg或25 mg应用对HbA1c水平的降低效果均显著优于安慰剂，其中25 mg剂量应用时的降糖效果不劣于二甲双胍或西格列汀，而不增加低血糖风险。依帕列净的低血糖风险与安慰剂相当，但尿路感染发生风险明显升高(OR=3.31)。

原始出处：


Liakos A1, Karagiannis T, Athanasiadou E, Sarigianni M, Mainou M, Papatheodorou K, Bekiari E, Tsapas A.Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.Diabetes Obes Metab. 2014 Apr 26. doi: 10.1111/dom.12307. [Epub ahead of print]


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1901207, encodeId=615c190120ed4, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 15 17:03:00 CST 2015, time=2015-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895723, encodeId=e4161895e2381, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Oct 07 15:03:00 CST 2014, time=2014-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759439, encodeId=0e271e59439a5, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Dec 02 21:03:00 CST 2014, time=2014-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887387, encodeId=2e17188e387a3, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Aug 22 07:03:00 CST 2014, time=2014-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636858, encodeId=82441636858d8, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Dec 31 04:03:00 CST 2014, time=2014-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417280, encodeId=5229141e280ed, content=<a href='/topic/show?id=266826884bf' target=_blank style='color:#2F92EE;'>#依帕列净#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26884, encryptionId=266826884bf, topicName=依帕列净)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0353248055, createdName=DEXTER3140, createdTime=Thu May 08 05:03:00 CST 2014, time=2014-05-08, status=1, ipAttribution=)]
    2015-02-15 木头人513

    #Diabetes#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1901207, encodeId=615c190120ed4, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 15 17:03:00 CST 2015, time=2015-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895723, encodeId=e4161895e2381, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Oct 07 15:03:00 CST 2014, time=2014-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759439, encodeId=0e271e59439a5, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Dec 02 21:03:00 CST 2014, time=2014-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887387, encodeId=2e17188e387a3, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Aug 22 07:03:00 CST 2014, time=2014-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636858, encodeId=82441636858d8, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Dec 31 04:03:00 CST 2014, time=2014-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417280, encodeId=5229141e280ed, content=<a href='/topic/show?id=266826884bf' target=_blank style='color:#2F92EE;'>#依帕列净#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26884, encryptionId=266826884bf, topicName=依帕列净)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0353248055, createdName=DEXTER3140, createdTime=Thu May 08 05:03:00 CST 2014, time=2014-05-08, status=1, ipAttribution=)]
    2014-10-07 一闲

    #MET#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1901207, encodeId=615c190120ed4, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 15 17:03:00 CST 2015, time=2015-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895723, encodeId=e4161895e2381, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Oct 07 15:03:00 CST 2014, time=2014-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759439, encodeId=0e271e59439a5, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Dec 02 21:03:00 CST 2014, time=2014-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887387, encodeId=2e17188e387a3, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Aug 22 07:03:00 CST 2014, time=2014-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636858, encodeId=82441636858d8, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Dec 31 04:03:00 CST 2014, time=2014-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417280, encodeId=5229141e280ed, content=<a href='/topic/show?id=266826884bf' target=_blank style='color:#2F92EE;'>#依帕列净#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26884, encryptionId=266826884bf, topicName=依帕列净)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0353248055, createdName=DEXTER3140, createdTime=Thu May 08 05:03:00 CST 2014, time=2014-05-08, status=1, ipAttribution=)]
    2014-12-02 智智灵药

    #BET#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1901207, encodeId=615c190120ed4, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 15 17:03:00 CST 2015, time=2015-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895723, encodeId=e4161895e2381, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Oct 07 15:03:00 CST 2014, time=2014-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759439, encodeId=0e271e59439a5, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Dec 02 21:03:00 CST 2014, time=2014-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887387, encodeId=2e17188e387a3, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Aug 22 07:03:00 CST 2014, time=2014-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636858, encodeId=82441636858d8, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Dec 31 04:03:00 CST 2014, time=2014-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417280, encodeId=5229141e280ed, content=<a href='/topic/show?id=266826884bf' target=_blank style='color:#2F92EE;'>#依帕列净#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26884, encryptionId=266826884bf, topicName=依帕列净)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0353248055, createdName=DEXTER3140, createdTime=Thu May 08 05:03:00 CST 2014, time=2014-05-08, status=1, ipAttribution=)]
    2014-08-22 guojianrong

    #Meta#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1901207, encodeId=615c190120ed4, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 15 17:03:00 CST 2015, time=2015-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895723, encodeId=e4161895e2381, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Oct 07 15:03:00 CST 2014, time=2014-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759439, encodeId=0e271e59439a5, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Dec 02 21:03:00 CST 2014, time=2014-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887387, encodeId=2e17188e387a3, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Aug 22 07:03:00 CST 2014, time=2014-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636858, encodeId=82441636858d8, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Dec 31 04:03:00 CST 2014, time=2014-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417280, encodeId=5229141e280ed, content=<a href='/topic/show?id=266826884bf' target=_blank style='color:#2F92EE;'>#依帕列净#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26884, encryptionId=266826884bf, topicName=依帕列净)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0353248055, createdName=DEXTER3140, createdTime=Thu May 08 05:03:00 CST 2014, time=2014-05-08, status=1, ipAttribution=)]
    2014-12-31 ms9608593228839890

    #DIA#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1901207, encodeId=615c190120ed4, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 15 17:03:00 CST 2015, time=2015-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895723, encodeId=e4161895e2381, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Oct 07 15:03:00 CST 2014, time=2014-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759439, encodeId=0e271e59439a5, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Dec 02 21:03:00 CST 2014, time=2014-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887387, encodeId=2e17188e387a3, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Aug 22 07:03:00 CST 2014, time=2014-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636858, encodeId=82441636858d8, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Dec 31 04:03:00 CST 2014, time=2014-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417280, encodeId=5229141e280ed, content=<a href='/topic/show?id=266826884bf' target=_blank style='color:#2F92EE;'>#依帕列净#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26884, encryptionId=266826884bf, topicName=依帕列净)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0353248055, createdName=DEXTER3140, createdTime=Thu May 08 05:03:00 CST 2014, time=2014-05-08, status=1, ipAttribution=)]
    2014-05-08 DEXTER3140

    #依帕列净#

    0

Baidu
map
Baidu
map
Baidu
map